Invention:
This invention relates to three types of ionic liquids (ILs) that will improve the delivery of a diverse array of therapeutic agents. The first type of ILs consists of a drug as either cation or anion and a biocompatible counterion to improve the aqueous or lipid solubility and permeability of drugs and to facilitate the incorporation of these ILs into various nano formulations. The second type of ILs consists of biocompatible and pharmaceutically acceptable cations and anions are used as a solvent to solubilize and deliver drugs with poor solubility and/or permeability. The third type of ILs consist of biocompatible cation and anion that, when added to water at a specific concentration, can form self-assembled nanostructures, which can package a variety of hydrophobic therapeutic agents.
Background:
Low-solubility and/or low permeability impact the delivery, bioavailability, and efficacy of therapeutic agents that are already approved or in the process of drug development. These reasons impact the delivery, bioavailability and efficacy of these therapeutic agents. Thus, ILs have emerged as the next-generation vehicle for drug delivery. Ionic liquids can be used as a solubility enhancer, permeability enhancer, stabilizer, targeted delivery inducer, stealth property provider or bioavailability enhancer. These ILs have the potential to make massive improvements in the development of drugs or vaccine dosage formulation.
Applications:
- Delivery of therapeutic agents
- Drug development
- Vaccine formulation
Advantages:
- Improves delivery with low solubility
- Improves delivery with permeability
- Various routes of administration
